Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Fintel reports that on May 19, 2025, RBC Capital downgraded their outlook for Biohaven (NYSE:BHVN) from Outperform to Sector ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biohaven Ltd (Symbol: BHVN), where a total volume of 12,755 contracts has been ...

US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment ...

Biohaven (NYSE:BHVN – Free Report) had its price objective reduced by Royal Bank of Canada from $61.00 to $54.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports.

Get free option data for BHVN. You'll find Call and Put Strike Prices, Last Price, Change, Volume, Implied Volatility, Theoretical and Greeks for Biohaven Pharma options for the expiration dates ...

The company announced some discouraging news from a major regulatory body. It will have to wait longer than expected on an application for a very promising developmental drug. After market close ...

FDA extends PDUFA date for troriluzole NDA to Q4 2025; advisory committee meeting planned, date to be decided. Troriluzole shows 50–70% slower disease progression in SCA and fall risk reduction ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called spinocerebellar ataxia. Read more here.

Price Action: BHVN stock is down 14.3% at $16.85 at the last check on Thursday. Read Next: China’s NetEase Stock Pops On Q1 Performance Fueled By Gaming Growth, Strong Cash Flow ...